SCHEMBL2865289

SCHEMBL2865289

O=C=Nc1cc2ccccc2oc1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.51
HPGD P15428 5/20 0.51
TYR P14679 1/20 0.51
DAO P14920 1/20 0.51
AKR1B1 P15121 1/20 0.51
POLB P06746 1/20 0.51
MAOB P27338 7/20 0.49
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 5/20 0.49
RAB9A P51151 4/20 0.49
CA12 O43570 3/20 0.47
CA9 Q16790 3/20 0.47
CA1 P00915 2/20 0.47
CA3 P07451 1/20 0.47
TSHR P16473 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
GPR35 Q9HC97 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30175364 0.85 HPGD (0.50) SMN1; SMN2HPGDTYRDAOAKR1B1
SCHEMBL9808744 0.85 HPGD (0.50) SMN1; SMN2HPGDTYRDAOAKR1B1
SCHEMBL30266969 0.82 HPGD (0.58) SMN1; SMN2HPGDTYRDAOAKR1B1
SCHEMBL8694950 0.80 HPGD (0.56) SMN1; SMN2HPGDTYRDAOAKR1B1
SCHEMBL1656932 0.77 CYP2A6 (0.44) SMN1; SMN2HPGDTYRDAOAKR1B1
SCHEMBL2229964 0.77 HPGD (0.56) SMN1; SMN2HPGDTYRDAOAKR1B1
SCHEMBL3052164 0.75 KDM4E (0.55) SMN1; SMN2HPGDMAOBKDM4EALDH1A1
SCHEMBL29589760 0.75 CYP3A4 (0.48) HPGDPOLBALDH1A1RAB9ACA1
SCHEMBL661077 0.75 CYP3A4 (0.48) HPGDPOLBALDH1A1RAB9ACA1
SCHEMBL29577532 0.75 HPGD (0.50) SMN1; SMN2HPGDTYRDAOAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2821430-A1 Siloxane polymers with central polysiloxane polymer block with organofunctional residues, each comprising at least two bivalent groups selected from urea and/or carbamate groups and at least one UV/Vis chromophore as residue Evonik Industries AG (DE) 2015-01-07 EP claimed
US-20150004112-A1 SILOXANE POLYMERS WITH A CENTRAL POLYSILOXANE POLYMER BLOCK WITH ORGANOFUNCTIONAL RADICALS EACH HAVING AT LEAST TWO BIVALENT GROUPS SELECTED FROM UREA AND/OR CARBAMATE GROUPS AND AT LEAST ONE UV/VIS CHROMOPHORE AS RADICAL EVONIK INDUSTRIES AG (DE) 2015-01-01 US claimed
EP-3280821-A2 DETECTION OF ONE OR MORE PATHOGENS Polyskope Labs (US) 2018-02-14 EP disclosed
WO-2016164407-A2 DETECTION OF ONE OR MORE PATHOGENS POLYSKOPE LABS (US) 2016-10-13 WO disclosed
US-9382254-B2 Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis GALAPAGOS NV (BE) 2016-07-05 US disclosed
EP-2821430-A1 Siloxane polymers with central polysiloxane polymer block with organofunctional residues, each comprising at least two bivalent groups selected from urea and/or carbamate groups and at least one UV/Vis chromophore as residue Evonik Industries AG (DE) 2015-01-07 EP disclosed
US-20150005275-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS. GALAPAGOS NV (BE) 2015-01-01 US disclosed
US-20150004112-A1 SILOXANE POLYMERS WITH A CENTRAL POLYSILOXANE POLYMER BLOCK WITH ORGANOFUNCTIONAL RADICALS EACH HAVING AT LEAST TWO BIVALENT GROUPS SELECTED FROM UREA AND/OR CARBAMATE GROUPS AND AT LEAST ONE UV/VIS CHROMOPHORE AS RADICAL EVONIK INDUSTRIES AG (DE) 2015-01-01 US disclosed
CN-102281893-A Vaccine strain of brachyspira hyodysenteriae 2011-12-14 CN disclosed
WO-2010054437-A1 VACCINE STRAINS OF BRACHYSPIRA HYODYSENTERIAE SPIROGENE PTY LTD (AU) 2010-05-20 WO disclosed
US-4877783-A β-lactam antibacterial agents BEECHAM GROUP P.L.C. (GB) 1989-10-31 US disclosed
EP-0071395-B1 BETA-LACTAM ANTIBACTERIAL AGENTS BEECHAM GROUP PLC (GB) 1988-08-10 EP disclosed
US-4609652-A FORMAMIDYL DERIVATIVES OF AMINO ACID DERIVATIVE ANTIBIOTICS BEECHAM GROUP P.L.C. (GB) 1986-09-02 US disclosed
US-4539149-A β-Lactam antibacterial agents BEECHAM GROUP P.L.C. (GB) 1985-09-03 US disclosed
EP-0071395-A1 Beta-lactam antibacterial agents BEECHAM GROUP PLC (GB) 1983-02-09 EP disclosed
US-4259506-A SELECTIVELY DESTROYING WEEDS IN CROPS PHILAGRO (FR) 1981-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150004112-A1 SILOXANE POLYMERS WITH A CENTRAL POLYSILOXANE POLYMER BLOCK WITH ORGANOFUNCTIONAL RADICALS EACH HAVING AT LEAST TWO BIVALENT GROUPS SELECTED FROM UREA AND/OR CARBAMATE GROUPS AND AT LEAST ONE UV/VIS CHROMOPHORE AS RADICAL CCNI, UBE2I, CCNB1 SMN1; SMN2 2824/4885HPGD 2693/4885TYR 4283/4885
US-20150005275-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS. CFTR, ABCC3, ABCC5 SMN1; SMN2 4483/4885HPGD 1909/4885TYR 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.